Terms: = Prostate cancer AND TSC2, FLJ43106, 7249, ENSG00000103197, LAM, tuberin, TSC4 AND Treatment
13 results:
1. Apoptotic Potential of Glucomoringin Isothiocyanate (GMG-ITC) Isolated from
Abd Karim NA; Adam AHB; Jaafaru MS; Rukayadi Y; Abdull Razis AF
Molecules; 2023 Apr; 28(7):. PubMed ID: 37049977
[TBL] [Abstract] [Full Text] [Related]
2. Pelvic magnetic resonance imaging parameters predict urinary incontinence after robot-assisted radical prostatectomy.
Sadahira T; Mitsui Y; Araki M; Maruyama Y; Wada K; Edamura K; Kobayashi Y; Watanabe M; Watanabe T; Nasu Y
Low Urin Tract Symptoms; 2019 May; 11(3):122-126. PubMed ID: 30548814
[TBL] [Abstract] [Full Text] [Related]
3. Health-Related Quality of Life in 536 Long-Term prostate cancer Survivors after treatment with Leuprorelin Acetate: A Combined Retrospective and Prospective Analysis.
Hammerer PG; Wirth MP;
Urol Int; 2018; 100(1):72-78. PubMed ID: 29183006
[TBL] [Abstract] [Full Text] [Related]
4. EGCG/gelatin-doxorubicin gold nanoparticles enhance therapeutic efficacy of doxorubicin for prostate cancer treatment.
Tsai LC; Hsieh HY; Lu KY; Wang SY; Mi FL
Nanomedicine (Lond); 2016 Jan; 11(1):9-30. PubMed ID: 26654241
[TBL] [Abstract] [Full Text] [Related]
5. AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf, and TSC1/tsc2.
Lin HP; Lin CY; Huo C; Jan YJ; Tseng JC; Jiang SS; Kuo YY; Chen SC; Wang CT; Chan TM; Liou JY; Wang J; Chang WS; Chang CH; Kung HJ; Chuu CP
Oncotarget; 2015 Sep; 6(29):27097-112. PubMed ID: 26318033
[TBL] [Abstract] [Full Text] [Related]
6. Multivariate analysis of factors predicting prostate dose in intensity-modulated radiotherapy.
Tomita T; Nakamura M; Hirose Y; Kitsuda K; Notogawa T; Miki K; Nakamura K; Ishigaki T
Med Dosim; 2014; 39(4):360-5. PubMed ID: 25155214
[TBL] [Abstract] [Full Text] [Related]
7. A unique amidoanthraquinone derivative displays antiproliferative activity against human hormone-refractory metastatic prostate cancers through activation of LKB1-AMPK-mTOR signaling pathway.
Hsu JL; Liu SP; Lee CC; Hsu LC; Ho YF; Huang HS; Guh JH
Naunyn Schmiedebergs Arch Pharmacol; 2014 Oct; 387(10):979-90. PubMed ID: 25005758
[TBL] [Abstract] [Full Text] [Related]
8. Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.
Misra UK; Pizzo SV
PLoS One; 2012; 7(12):e51735. PubMed ID: 23272152
[TBL] [Abstract] [Full Text] [Related]
9. Dose-effect relationships for individual pelvic floor muscles and anorectal complaints after prostate radiotherapy.
Smeenk RJ; Hoffmann AL; Hopman WP; van Lin EN; Kaanders JH
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):636-44. PubMed ID: 22137024
[TBL] [Abstract] [Full Text] [Related]
10. Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells.
Suh Y; Afaq F; Khan N; Johnson JJ; Khusro FH; Mukhtar H
Carcinogenesis; 2010 Aug; 31(8):1424-33. PubMed ID: 20530556
[TBL] [Abstract] [Full Text] [Related]
11. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
[TBL] [Abstract] [Full Text] [Related]
12. Blockade of AKT activation in prostate cancer cells with a small molecule inhibitor, 9-chloro-2-methylellipticinium acetate (CMEP).
Zhang M; Fang X; Liu H; Wang S; Yang D
Biochem Pharmacol; 2007 Jan; 73(1):15-24. PubMed ID: 16950208
[TBL] [Abstract] [Full Text] [Related]
13. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.
Xu Y; Chen SY; Ross KN; Balk SP
Cancer Res; 2006 Aug; 66(15):7783-92. PubMed ID: 16885382
[TBL] [Abstract] [Full Text] [Related]
